Archivio istituzionale della ricerca dell'Università degli Studi di Palermo

COMELLA P, FILIPPELLI G, MASSIDDA B, PUTZU C, NATALE D, PALMERI S, et al. (2006). “OXXEL (oxaliplatin plus Xeloda) vs OXAFAFU (oxaliplatin plus folinic acid-modulated 5-fluorouracil i.v. bolus) every 2 weeks in metastatic colorectal carcinoma (MCC): preliminary safety and activity analysis of a Southern Italy Cooperative Oncology Group (SICOG) phase III trial”. ??????? it.cilea.surplus.oa.citation.tipologie.CitationProceedings.prensentedAt ??????? World Congress on Gastrointestinal Cancer.

“OXXEL (oxaliplatin plus Xeloda) vs OXAFAFU (oxaliplatin plus folinic acid-modulated 5-fluorouracil i.v. bolus) every 2 weeks in metastatic colorectal carcinoma (MCC): preliminary safety and activity analysis of a Southern Italy Cooperative Oncology Group (SICOG) phase III trial”

PALMERI, Sergio;
2006-01-01
World Congress on Gastrointestinal Cancer
2006
abs O-016
COMELLA P, FILIPPELLI G, MASSIDDA B, PUTZU C, NATALE D, PALMERI S, et al. (2006). “OXXEL (oxaliplatin plus Xeloda) vs OXAFAFU (oxaliplatin plus folinic acid-modulated 5-fluorouracil i.v. bolus) every 2 weeks in metastatic colorectal carcinoma (MCC): preliminary safety and activity analysis of a Southern Italy Cooperative Oncology Group (SICOG) phase III trial”. ??????? it.cilea.surplus.oa.citation.tipologie.CitationProceedings.prensentedAt ??????? World Congress on Gastrointestinal Cancer.
Proceedings (atti dei congressi)
COMELLA P; FILIPPELLI G; MASSIDDA B; PUTZU C; NATALE D; PALMERI S; MAIORINO L; CONDEMI G; LEO S GAMBARDELLA A
Proceedings
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10447/11407
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? 0
social impact